Arcturus Therapeutics Ltd Forecast, price target & analysts
Arcturus Therapeutics Ltd Target price 2025 - Analyst rating & recommendation
Arcturus Therapeutics Ltd Classifications & Recommendation:
Arcturus Therapeutics Ltd Price Target
| Target Price | $55.59 |
| Price | $16.70 |
| Potential |
232.87%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Arcturus Therapeutics Ltd 2026 .
The average Arcturus Therapeutics Ltd target price is $55.59.
This is
232.87%
register free of charge
$147.00
780.24%
register free of charge
$25.25
51.20%
register free of charge
|
|
| A rating was issued by 18 analysts: 17 Analysts recommend Arcturus Therapeutics Ltd to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Arcturus Therapeutics Ltd stock has an average upside potential 2026 of
232.87%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 152.31 | 100.34 |
| 8.69% | 34.12% | |
| EBITDA Margin | -60.49% | -98.29% |
| 34.08% | 62.49% | |
| Net Margin | -53.14% | -70.09% |
| 198.15% | 31.89% |
13 Analysts have issued a sales forecast Arcturus Therapeutics Ltd 2025 . The average Arcturus Therapeutics Ltd sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Arcturus Therapeutics Ltd EBITDA forecast 2025. The average Arcturus Therapeutics Ltd EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Arcturus Therapeutics Ltd Analysts have issued a net profit forecast 2025. The average Arcturus Therapeutics Ltd net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.00 | -2.59 |
| 167.86% | 13.67% | |
| P/E | negative | |
| EV/Sales | 2.56 |
13 Analysts have issued a Arcturus Therapeutics Ltd forecast for earnings per share. The average Arcturus Therapeutics Ltd EPS is
This results in the following potential growth metrics and future valuations:
Arcturus Therapeutics Ltd...
Current Arcturus Therapeutics Ltd Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Leerink Partners |
Locked
➜
Locked
|
Locked | Aug 22 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Jul 02 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | May 28 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | May 14 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | May 13 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Aug 22 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 12 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 12 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Jul 02 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
May 28 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
May 14 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
May 13 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
